Safety of primary immunization with a DTwP-HBV/Hib vaccine in healthy infants: a prospective, open-label, interventional, phase IV clinical study

References

• [WHO] World Health Organization. Vaccines and immunization. [cited 2021 Mar 30]. Available from: https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1.
   Google Scholar
• Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care. 2003;9((1)Suppl):S6–12.
   PubMed Web of Science ®Google Scholar
• Ward BJ. Vaccine adverse events in the new millennium: is there reason for concern? Bull World Health Organ. 2000;78(2):205–215.
   PubMed Web of Science ®Google Scholar
• [CDC] Centers for Disease Control and Prevention. Combination vaccines for childhood immunization. MMWR Recomm Rep. 1999May14;48(RR–5):1–14. cited on 2021 Mar 2021. Available from. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr4805a1.htm
   Google Scholar
• Maman K, Zöllner Y, Greco D, et al. The value of childhood combination vaccines: from beliefs to evidence. Hum Vaccin Immunother. 2015;11(9):2132–2141.
   PubMed Web of Science ®Google Scholar
• Gatchalian S, Reyes M, Bernal N, et al. A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth. Hum Vaccin. 2005;1(5):198–203.
   PubMed Web of Science ®Google Scholar
• Bavdekar SB, Maiya PP, Subba Rao SD, et al. Immunogenicity and safety of combined diphtheria tetanus whole cell pertussis hepatitis B/ Haemophilus influenzae type b vaccine in Indian infants. Indian Pediatr. 2007;44(7):505–510.
   PubMed Web of Science ®Google Scholar
• Bar-On ES, Goldberg E, Hellmann S, et al. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). Cochrane Database Syst Rev. 2012;4:CD005530.
   Google Scholar
• Kanra G, Kara A, Demiralp O, et al. Safety andimmunogenicity of a new fully liquid DTPw-HepB-Hib combination vaccine ininfants. Hum Vaccin. 2006;2(4):155–160.
   PubMed Web of Science ®Google Scholar
• Su Á Rez E, Asturias EJ, Hilbert AK, et al. A fully liquidDTPw-HepB-Hib combination vaccine for booster vaccination of toddlers in El Salvador. Rev Panam Salud Publica. 2010;27(2):117–124.
   PubMed Web of Science ®Google Scholar
• Prymula R, David MP, Lefevre I, et al. The immunogenicity and reactogenicity of a new DTPw-HBV vaccine as a primary and booster vaccination course in healthy infants. Hum Vaccin. 2007;3(4):121–126.
   PubMed Web of Science ®Google Scholar
• Riedemann S, Reinhardt G, Jara J, et al. Immunogenicity and reactogenicity of combined versus separately administered DTPw-HBV and Hib vaccines given to healthy infants at 2, 4 and 6 months of age, with a booster at 18 months. Int J Infect Dis. 2002;6(3):215–222.
   PubMedGoogle Scholar
• Santos JI, Martin A, De Leon T, et al. DTPw-HB and Hib primary and booster vaccination: combined versus separate administration to Latin American children. Vaccine. 2002;20(13–14):1887–1893.
   PubMed Web of Science ®Google Scholar
• Arístegui J, Usonis V, Coovadia H, et al. Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine. Int J Infect Dis. 2003;7(2):143–151.
   PubMedGoogle Scholar
• Faingezicht I, Avila-Aguerro ML, Cervantes Y, et al. Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine. Rev Panam Salud Publica. 2002;12(4):247–257.
   PubMedGoogle Scholar
• [WHO] World Health Organization. Pentavalent vaccine in Asian countries; 2013. accessed on 2021 Nov 11. Available from: https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/pentavalent-vaccine
   Google Scholar
• Tam J, Tran D, Bettinger JA, et al. Canadian immunization monitoring program active investigators. review of pediatric encephalitis and encephalopathy cases following immunization reported to the Canadian Immunization Monitoring Program Active (IMPACT) from 1992 to 2012. Vaccine. 2020 Jun 9 38(28):4457–4463.
   PubMed Web of Science ®Google Scholar
• Sun Y, Christensen J, Hviid A, et al. Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type B. JAMA. 2012 Feb 22 307(8):823–831.
   PubMed Web of Science ®Google Scholar
• Miller D, Wadsworth J, Ross E. Severe neurological illness: further analyses of the British National Childhood Encephalopathy Study. Tokai J Exp Clin Med. 1988;13(Suppl):145–155.
   PubMedGoogle Scholar
• Barlow WE, Davis RL, Glasser JW, et al. Centers for Disease Control and Prevention Vaccine Safety Datalink Working Group. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med. 2001 Aug 30 345(9):656–661.
   PubMedGoogle Scholar
• Cowan LD, Griffin MR, Howson CP, et al. Acute encephalopathy and chronic neurological damage after pertussis vaccine. Vaccine. 1993;11(14):1371–1379.
   PubMed Web of Science ®Google Scholar
• Monteiro SA, Takano OA, Waldman EA. Surveillance for adverse events after DTwP/Hib vaccination in Brazil: sensitivity and factors associated with reporting. Vaccine. 2010;28(18):3127–3133.
   PubMed Web of Science ®Google Scholar
• [WHO]World Health Organization. Expert committee on biological standardization. Annex 9. In: WHO Technical Report Series No. 1004. sixty-seventh report. Guidelines on clinical evaluation of vaccines: regulatory expectations. Replacement of annex 1 of WHO Technical Report Series, No. 924. Geneva: WHO Press, 2017:503–573.
   Google Scholar
• Asturias EJ, Contreras-Roldan IL, Ram M, et al. Post-authorization safety surveillance of a liquid pentavalent vaccine in Guatemalan children. Vaccine. 2013;31(49):5909–5914.
   PubMed Web of Science ®Google Scholar
• Mehmeti I, Bino S, Nelaj E, et al. Adverse events following administration of DTwP containing vaccines in Albanian children from 2003 to 2015. ESJ. 2016;12(33):40.
   Google Scholar
• Ducusin J, Dayrit E, Simbulan A, et al. Post-marketing surveillance study of a combined diphtheria, tetanus, whole-cell pertussis, and hepatitis B vaccine in the Philippines. Southeast Asian J Trop Med Public Health. 2000 Sep;31(3):487–492.
   PubMedGoogle Scholar
• Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev. 2010;23(1):74–98.
   PubMed Web of Science ®Google Scholar
• Gruber WC. The epidemiology of respiratory infections in children. Semin Pediatr Infect Dis. 1995;6(2):49–56.
   PubMedGoogle Scholar
• Maródi L. Neonatal innate immunity to infectious agents. Infect Immun. 2006;74(4):1999–2006.
   PubMed Web of Science ®Google Scholar
• Duffy J, Hambidge SJ, Jackson LA, et al. Febrile seizure risk after vaccination in children one to five months of age. Pediatr Neurol. 2017;76:72–78.
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Wise L, et al. Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United Kingdom. Vaccine. 2010;28(44):7215–7220.
   PubMed Web of Science ®Google Scholar
• [WHO] World Health Organization. information sheet observed rate of vaccine reactions diphtheria, pertussis, tetanus vaccines. cited on 2021 Nov 10]. Available from 2021 Nov 10: https://www.who.int/vaccine_safety/initiative/tools/DTP_vaccine_rates_information_sheet.pdf
   Google Scholar
• [WHO] World Health Organization. Pneumonia. cited on 2021 Nov 11]. cited 2021 Nov 11 from https://www.who.int/news-room/fact-sheets/detail/pneumonia
   Google Scholar
• Chatterjee S, Rego SJ, D’Souza F, et al. The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule. BMC Infect Dis. 2010;10(1):298.
   PubMedGoogle Scholar
• Rusmil K, Gunardi H, Fadlyana E, et al. The immunogenicity, safety, and consistency of an Indonesia combined DTP-HB-Hib vaccine in expanded program on immunization schedule. BMC Pediatr. 2015;15(1):219.
   PubMedGoogle Scholar